- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Publication
Slideshow
Dermatology Times
Dermatology Times, July 2018 (Vol. 39, No. 07)Volume39 Issue 7
Four questions every provider should ask about digital technology
Author(s):
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.See:Â "More patients want digital health"Â
Articles in this issue
Pricing patients out of healthcare?
Image IQ: When is a biopsy required?
Rare tumors and fibrotic skin lesions
New Drugs Roundup: Dermatology
The top 7 mobile apps in dermatology
Medicine no longer apolitical
Study: Novel 670 nm wavelength works for benign pigmented lesions
I use social media and now I might lose my license?
Complications low with chemical peels in darker skin
Non-physician operators target of most legal action for laser procedures
Where full-field erbium outshines fractional
eConsults support underserved patients
Considerations for diagnosing eosinophilic fasciitis
Avoid antibiotics for acne treatment when possible
Is it acne or Pityrosporum folliculitis?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Understanding the Role of OX40 in Next-Generation Eczema Therapies
Jonathan Silverberg, MD, PhD, MPH on Keeping Up With Rapid AD Developments
The Vicious Cycle of Itch, Stress, and Sleep Loss
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
Related Content
